海吉亞醫療(06078.HK)擬收購長三角一所二級甲等綜合醫院70%股權
海吉亞醫療(06078.HK)宣布,於今日(12日)與潛在賣方訂立不具法律約束力的意向書,或以增資或股權轉讓形式,收購位於長三角地區一所二級甲等綜合醫院不低於70%的股權,收購事項細節將進行進一步磋商。截至目前,潛在賣方持有該醫院的100%股權,並預期於交易完成後繼續持有剩餘股權。
集團表示,長三角地區人口眾多,對腫瘤醫療服務有較高需求,預期收購與擴張戰略一致,鑒於該醫院於所在城市具備較好的經濟基礎及地理優勢,認為具有強大發展潛力,可於未來持續擴張產能,並有利於集團整合該醫院與蘇州滄浪醫院、蘇州永鼎醫院及無錫海吉亞醫院待資源,進一步提升長三角業務協同效應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.